Gut bacteria boosts immunotherapy in kidney cancer trial
NCT ID NCT07037004
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding a live bacteria product called CBM588 to the immunotherapy drug pembrolizumab can help prevent kidney cancer from coming back after surgery. About 62 adults with high-risk clear cell or sarcomatoid kidney cancer will receive either pembrolizumab alone or pembrolizumab plus CBM588. The goal is to see if changing the gut microbiome improves the immune response and reduces recurrence.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
-
City of Hope at Irvine Lennar
RECRUITINGIrvine, California, 92618, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged immune attack shrink kidney tumors before surgery?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Old drug, new hope: mercaptopurine tested against rare cancer syndrome
- Drug cocktail aims to shrink kidney tumors before surgery and prevent return
- Immunotherapy after kidney surgery may delay cancer return in rare kidney cancer